Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a virtual board help doctors tackle prostate cancer genetics?

NCT ID NCT04789018

Knowledge-focused Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study looks at whether a web-based virtual genetics board helps doctors discuss and manage prostate cancer genetics. About 118 healthcare providers, including oncologists and genetic counselors, will use the board and then give feedback through surveys and interviews. The goal is to see if the tool is useful and easy to use, not to directly treat patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Educational intervention (virtual genetics board)
What this could lead to
If successful, this could lead to a tool that helps doctors better use genetic information to treat and screen for prostate cancer.
What could go wrong
This is a small, early-stage study focused on provider opinions, not patient outcomes. The tool may not prove useful or practical in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

118 people

The number who actually took part.

Started

Jan 2020

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Non-genetic providers who perform prostate cancer (PCA) genetic testing for men in their practices (medical oncologists, radiation oncologists, urologists, primary care providers, mid-level providers)

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Individuals must meet one of the following inclusion criteria in order to be eligible to participate in the study: * Healthcare providers (medical oncologists, radiation oncologists, urologists, primary care providers, mid-level providers) who evaluate, manage, or treat men with prostate cancer or screen men for prostate cancer. * Providers who perform prostate cancer genetic testing for men (genetic counselors or healthcare providers) * Scientists and researchers * Advocacy or patient stakeholder organization members Exclusion Criteria: • Non-medical providers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate carcinoma

Contacts and locations

Locations

  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.